Results 31 to 40 of about 12,862 (201)

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.

PLoS ONE, 2021
BackgroundDirect-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people.
Lisa Townshend-Bulson, Elena Roik, Youssef Barbour, Dana J T Bruden, Chriss E Homan, Hannah G F Espera, Timothy J Stevenson, Annette M Hewitt, Wileina Rhodes, James E Gove, Julia N Plotnik, Mary M Snowball, John McGilvray, Brenna C Simons, Janet M Johnston, Brian J McMahon   +15 more
doaj   +1 more source

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. [PDF]

PLoS Neglected Tropical Diseases, 2019
Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection
Caroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, André C Ferreira, Patrícia A Reis, Rodrigo Delvecchio, Fabio L Monteiro, Giselle Barbosa-Lima, Harrison James Westgarth, Yasmine Rangel Vieira, Mayara Mattos, Natasha Rocha, Lucas Villas Bôas Hoelz, Rennan Papaleo Paes Leme, Mônica M Bastos, Gisele Olinto L Rodrigues, Carla Elizabeth M Lopes, Celso Martins Queiroz-Junior, Cristiano X Lima, Vivian V Costa, Mauro M Teixeira, Fernando A Bozza, Patrícia T Bozza, Nubia Boechat, Amilcar Tanuri, Thiago Moreno L Souza   +25 more
doaj   +1 more source

Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. [PDF]

PLoS ONE, 2015
In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbuvir-based treatment compared to current standard treatment in ...
Alena M Pfeil, Oliver Reich, Ines M Guerra, Sandrine Cure, Francesco Negro, Beat Müllhaupt, Daniel Lavanchy, Matthias Schwenkglenks   +7 more
doaj   +1 more source

Virological Responses in Chronic Hepatitis C Patients, Treated with Sofosbuvir and Declacavir Versus Sofosbuvir and Ribazole

, 2018
Objective: To determine the virological responses in chronic hepatitis c patients, treated with sofosbuvir and declacavir versus sofosbuvir and ribavirin at tertiary care Hospital Study Design And Setting: This was a prospective comparative study and was
Ali Jamali, Anwar
core   +1 more source

Co-crystallization of Sofosbuvir with Sugars for Enhanced Dissolution Rate

, 2023
Sofosbuvir is one of the direct acting antiviral agents which is approved in the treatment of chronic HCV in combination with other agents. The low aqueous solubility of sofosbuvir resulted in slow dissolution which is supposed to be responsible for its ...
El Maghraby, Gamal Mohamed, Mousa, Taher Mohamed Yassen, Donia, Ahmed Atef   +2 more
core   +1 more source

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes

Scientific Reports
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs.
Rana A. Ali, Eatemad A. Awadalla, Yahia A. Amin, Samer S. Fouad, Maha Abd-El Baki Ahmed, Mohammed H. Hassan, Emaad Abdel-Kahaar, Rehab H. Abdel-Aziz   +7 more
doaj   +1 more source

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D

Pakistan Armed Forces Medical Journal, 2020
Objective: To assess the safety and efficacy of Sofosbuvir based Antiviral regimens for chronic hepatitis C virus infected patients with chronic kidney disease stage 3 to stage 5D on haemodialysis. Study Design: Quasi experimental study.
Nauman Kashif, Zahid Farooq Baig, Shahzad Ashraf   +2 more
doaj  

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Journal of Virus Eradication, 2016
Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak   +3 more
doaj   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Sofosbuvir as treatment against dengue?

, 2017
Dengvaxia® (CTD-TDV), the only licensed tetravalent dengue vaccine by Sanofi Pasteur, was made available since 2015. However, administration of CTD-TDV, in general, has not received the prequalification recommendation from the World Health Organization ...
Yusof, Rohana, Lim, See Khai, Gan, Chye Sheng, Heh, Choon Han, Chee, Chin Fei   +4 more
core   +1 more source